BioWorld Asia

Nov. 8, 2006

Intercell Gets $9.5M Up Front In Potential $85M Merck Deal

Intercell AG earned an up-front payment of $9.5 million and could receive up to $76 million more in milestones from an agreement with Merck Sharpe & Dhome Research Ltd., an arm of Merck & Co. Inc. (BioWorld International) Read More

Archimedes Builds Portfolio Through Acquisition Of Link

Target Discovered That Could Help In Muscle Regeneration

European Union Tightens Rules On Human Cells And Tissues

Innate Pharma Completes €30M Initial Public Offering In Paris

No Abstract Read More

IntegraGen, Royal DSM Partner In Area Of Weight Management

UK Streamlines Process For Conducting Trials In Patients

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Dec. 22, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 22, 2025.

In 2025, science’s biggest story was political

BioWorld

In 2025, science saw its breakthroughs, which BioWorld will be covering as part of our end-of-the-year wrap-up. But the biggest science story of 2025 is not about...

Abstract blue human heart with red cardio pulse line and red circle

FDA says yes to Cytokinetics’ aficamten, now Myqorzo, in oHCM

BioWorld

Cytokinetics Inc. scored U.S. FDA marketing clearance Dec. 19 for Myqorzo (aficamten) 5-mg, 10-mg, 15-mg, and 20-mg tablets to improve functional capacity and...

Conjugating ferrocene to GPX4 inhibitors to promote ferroptosis

BioWorld Science

Small molecules that induce iron-dependent oxidative cell death known as ferroptosis can be effective against tumors that are resistant to other therapies....